CoChat
Sign Up
Cited by 201

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Dendritic cell derived exosomes loaded neoantigens for personalized cancer immunotherapies

Li, Ji, Li, Jiajia, Peng, Yiwei, Du, Yitian, Yang, Zhenzhen, Qi, Xianrong·2023·Journal of Controlled Release
DOI 10.1016/j.jconrel.2022.11.053
Open this paper in CoChat — free account

Abstract

Despite the promising potential of cancer vaccine, their efficacy has been limited in clinical trials and improved methods are urgently needed. Here we designed a nanovaccine platform that contains dendritic cell derived exosomes carriers and patient-specific neoantigens for individualized immunotherapies. The nanovaccine exhibited convenient cargo loading and prolonged cargo transportation to the lymph nodes, followed by eliciting potent antigen specific broad-spectrum T-cell and B-cell-mediated immune responses with great biosafety and biocompatibility. Strikingly, delivery of neoantigen-exosome nanovaccine significantly prohibited tumor growth, prolonged survival, delayed tumor occurrences with long-term memory, eliminated the lung metastasis in the therapeutic, prophylactic and metastatic B16F10 melanoma as well as therapeutic MC-38 models, respectively. Additionally, exosome-based nanovaccine demonstrated synergistic antitumor response superior to liposomal formulation due to presence of exosomal proteins. Collectively, our research indicated improved strategies for cell free vaccines and suggested exosome-based nanoplatform for cancer immunotherapy and personalized nanotechnology. These findings represent a powerful pathway to generate individualized nanovaccine rapidly for clinical application.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.jconrel.2022.11.053

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 37

  1. Garg, 2017, Integrating next-generation dendritic cell vaccines into the current Cancer immunotherapy landscape, Trends Immunol., 38, 577, 10.1016/j.it.2017.05.006 · DOI · Paper page
  2. L. Z, 1998, Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes, Nat. Med., 4, 594, 10.1038/nm0598-594 · DOI
  3. Viaud, 2010, Dendritic cell-derived exosomes for cancer immunotherapy: what’s next?, Cancer Res., 70, 1281, 10.1158/0008-5472.CAN-09-3276 · DOI
  4. Pitt, 2016, Dendritic cell-derived exosomes for cancer therapy, J. Clin. Invest., 126, 1224, 10.1172/JCI81137 · DOI · Paper page
  5. Escudier, 2005, Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial, J. Transl. Med., 3, 10, 10.1186/1479-5876-3-10 · DOI
  6. Morse, 2005, A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer, J. Transl. Med., 3, 9, 10.1186/1479-5876-3-9 · DOI
  7. Besse, 2016, Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC, Oncoimmunology, 5, 10.1080/2162402X.2015.1071008 · DOI · Paper page
  8. Hu, 2018, Towards personalized, tumour-specific, therapeutic vaccines for cancer, Nat. Rev. Immunol., 18, 168, 10.1038/nri.2017.131 · DOI · Paper page
  9. Castle, 2012, Exploiting the mutanome for tumor vaccination, Cancer Res., 72, 1081, 10.1158/0008-5472.CAN-11-3722 · DOI
  10. Kreiter, 2015, Mutant MHC class II epitopes drive therapeutic immune responses to cancer, Nature, 520, 692, 10.1038/nature14426 · DOI · Paper page
  11. Keskin, 2019, Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial, Nature, 565, 234, 10.1038/s41586-018-0792-9 · DOI · Paper page
  12. Yarchoan, 2017, Targeting neoantigens to augment antitumour immunity, Nat. Rev. Cancer, 17, 209, 10.1038/nrc.2016.154 · DOI · Paper page
  13. Naslund, 2013, Dendritic cell-derived exosomes need to activate both T and B cells to induce antitumor immunity, J. Immunol., 190, 2712, 10.4049/jimmunol.1203082 · DOI
  14. Alvarez-Erviti, 2011, Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes, Nat. Biotechnol., 29, 341, 10.1038/nbt.1807 · DOI · Paper page
  15. Tian, 2012, A membrane vesicle-based dual vaccine against melanoma and Lewis lung carcinoma, Biomaterials, 33, 6147, 10.1016/j.biomaterials.2012.05.034 · DOI
  16. Su Chul Jang, 2013, Bioinspired exosome-mimetic Nanovesicles for targeted delivery of chemotherapeutics toMalignant tumors, ACS Nano, 7, 13
  17. Qi, 2016, Blood exosomes endowed with magnetic and targeting properties for Cancer therapy, ACS Nano, 10, 3323, 10.1021/acsnano.5b06939 · DOI · Paper page
  18. Saari, 2015, Microvesicle- and exosome-mediated drug delivery enhances the cytotoxicity of paclitaxel in autologous prostate cancer cells, J. Control. Release, 220, 727, 10.1016/j.jconrel.2015.09.031 · DOI · Paper page
  19. Jiang, 2017, Lymph node targeting strategies to improve vaccination efficacy, J. Control. Release, 267, 47, 10.1016/j.jconrel.2017.08.009 · DOI
  20. Guo, 2015, Erythrocyte membrane-enveloped polymeric nanoparticles as nanovaccine for induction of antitumor immunity against melanoma, ACS Nano, 9, 6918, 10.1021/acsnano.5b01042 · DOI
  21. Zhang, 2019, Targeted Codelivery of an antigen and dual agonists by hybrid nanoparticles for enhanced Cancer immunotherapy, Nano Lett., 19, 4237, 10.1021/acs.nanolett.9b00030 · DOI
  22. Luo, 2017, A STING-activating nanovaccine for cancer immunotherapy, Nat. Nanotechnol., 12, 648, 10.1038/nnano.2017.52 · DOI
  23. Wang, 2018, “minimalist” Nanovaccine constituted from near whole antigen for Cancer immunotherapy, ACS Nano, 12, 6398, 10.1021/acsnano.8b00558 · DOI
  24. Chen, 2019, Nanoparticle-enhanced radiotherapy to trigger robust Cancer immunotherapy, Adv. Mater., 31, 10.1002/adma.201802228 · DOI
  25. Xu, 2013, Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis, J. Control. Release, 172, 259, 10.1016/j.jconrel.2013.08.021 · DOI
  26. Mosmann, 1989, TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties, Annu. Rev. Immunol., 7, 145, 10.1146/annurev.iy.07.040189.001045 · DOI · Paper page
  27. Wilson, 2013, pH-responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides, ACS Nano, 7, 3912, 10.1021/nn305466z · DOI
  28. Kuai, 2017, Designer vaccine nanodiscs for personalized cancer immunotherapy, Nat. Mater., 16, 489, 10.1038/nmat4822 · DOI
  29. Zhu, 2017, Intertwining DNA-RNA nanocapsules loaded with tumor neoantigens as synergistic nanovaccines for cancer immunotherapy, Nat. Commun., 8, 1482, 10.1038/s41467-017-01386-7 · DOI
  30. Kuai, 2018, Subcutaneous Nanodisc vaccination with Neoantigens for combination Cancer immunotherapy, Bioconjug. Chem., 29, 771, 10.1021/acs.bioconjchem.7b00761 · DOI
  31. Shae, 2020, Co-delivery of peptide Neoantigens and stimulator of interferon genes agonists enhances response to Cancer vaccines, ACS Nano, 14, 9904, 10.1021/acsnano.0c02765 · DOI
  32. Moon, 2011, Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses, Nat. Mater., 10, 243, 10.1038/nmat2960 · DOI
  33. Sanchez-Paulete, 2017, Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy, Ann. Oncol., 28, xii44, 10.1093/annonc/mdx237 · DOI
  34. Allison, 1974, Liposomes as immunological adjuvants, Nature, 252, 252, 10.1038/252252a0 · DOI
  35. Chatzikleanthous, 2021, Lipid-based nanoparticles for delivery of vaccine adjuvants and antigens: toward multicomponent vaccines, Mol. Pharm., 18, 2867, 10.1021/acs.molpharmaceut.1c00447 · DOI
  36. Nisini, 2018, The multirole of liposomes in therapy and prevention of infectious diseases, Front. Immunol., 9, 155, 10.3389/fimmu.2018.00155 · DOI
  37. Perrie, 2016, Designing liposomal adjuvants for the next generation of vaccines, Adv. Drug Deliv. Rev., 99, 85, 10.1016/j.addr.2015.11.005 · DOI

Cited by

Sorted by citations

See all 201

Metadata

Authors
Li, J., Li, J., Peng, Y., Du, Y., Yang, Z., & Qi, X.
Venue
Journal of Controlled Release
Publisher
Elsevier BV
Published
2023-01
Volume
353
Pages
423-433
ISSN
0168-3659
DOI
10.1016/j.jconrel.2022.11.053
Cited by
201
References
10
Language
en
Licence
Funders
  • National Natural Science Foundation of China (81973258)
  • Natural Science Foundation of Beijing Municipality (7202092, L202044)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review